Inclusion Criteria:

- subjects with non-myeloid malignancies

- anemia due to cancer

- ECOG status 0 to 2

- greater than or equal to 4-month expectancy

- greater than or equal to 18 years and of legal age for informed consent

- screening hemoglobin concentration less than or equal to 11.0g/dL

- adequate serum folate and vitamin B12

- adequate renal and liver function

- written informed consent

Exclusion Criteria:

- subjects currently receiving or planned to receive cytotoxic chemotherapy or
myelosuppressive radiotherapy during the study or within 4 weeks before randomization

- in complete remission, as determined by the investigator

- subjects who have other diagnoses not related to the cancer which cause anemia (eg.
gastrointestinal bleeding, renal disease, etc)

- documented history of pure red cell aplasia

- Known history of seizure disorder

- cardiac condition: uncontrolled angina, congestive heart failure, known ejection
fraction less than 40%, or uncontrolled cardiac arrhythmia

- uncontrolled hypertension

- clinically significant systemic infection or chronic inflammatory disease present at
the time of randomization

- iron deficiency

- known positive test for HIV infection

- previously suspected of or confirmed to have neutralizing antibodies to rHuEPO or
darbepoetin alfa

- received rHuEPO or darbepoetin alfa therapy within 4 weeks of randomization

- less than 30 days since receipt of any investigational drug or device that is not
approved by the applicable regulatory authority

- pregnant or breast feeding

- subject of reproductive potential who is not using adequate contraceptive precautions

- known hypersensitivity to mammalian-derived product or any other ingredients in the
investigational product

- previously randomized into this study

- concerns for subject's compliance with the protocol procedures